Anti-CD33 CAR T-cells vs Gemtuzumab Ozogamicin

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Acute Myeloid Leukemia

Shared mechanism: CD33 · full Acute Myeloid Leukemia pipeline

Anti-CD33 CAR T-cells

Developed by iCell Gene Therapeutics

Phase 1 in Acute Myeloid LeukemiaCAR-T
Weak signal

NCT05445765 · Phase 1 · status unknown

This is a small, single-arm, open-label dose-escalation study with no comparator group, designed to characterize the toxicity profile of this cell therapy. Results have not yet been posted.

No aligned efficacy figure on record for this race.

Gemtuzumab Ozogamicin

Marketed by Pfizer

Approved in Acute Myeloid Leukemiaantibody-drug conjugate
Partial signal

NCT00052299 · Phase 3 · completed

The trial was randomized and actively controlled, with 472 participants, but it was open-label rather than blinded. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Next expected readout: December 2026 · NCT03737955 (registry estimate)

Reported efficacy

Overall survival (OS) (four years): Short-term event-free survival at 6-month follow-up: 53% standard vs 58% gemtuzumab ozogamicin (HR 0·83; p=0·10); 2-year overall survival: 69% vs 73% (0·90; p=0·43) (missed)

Result source: NCT00893399

Results for Acute Myeloid Leukemia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAnti-CD33 CAR T-cellsGemtuzumab Ozogamicin
OS, median—Not reported27.9bn 138NCT00049517
2 other results
Complete remission—Not reported69% vs 68.6%vs Ara-C+Daunomycinn 300NCT00085709
Event-free survival, median—Not reported—Not posted · NCT02473146
Duration of response, median—Not reported—Not posted · NCT02473146

OS, median

Anti-CD33 CAR T-cells
—Not reported
Gemtuzumab Ozogamicin
27.9bn 138NCT00049517
2 other results

Complete remission

Anti-CD33 CAR T-cells
—Not reported
Gemtuzumab Ozogamicin
69% vs 68.6%vs Ara-C+Daunomycinn 300NCT00085709

Event-free survival, median

Anti-CD33 CAR T-cells
—Not reported
Gemtuzumab Ozogamicin
—Not posted · NCT02473146

Duration of response, median

Anti-CD33 CAR T-cells
—Not reported
Gemtuzumab Ozogamicin
—Not posted · NCT02473146
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Anti-CD33 CAR T-cells: no structured comparison results are available for Acute Myeloid Leukemia.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Anti-CD33 CAR T-cells: 0 of 4 rows · Gemtuzumab Ozogamicin: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricGemtuzumab Ozogamicin
Dropout rate
96.1%a
NCT03727750 · Phase 4 · registry result, not featured evidence
show 10 more results
16.7%Ara-C+Daunomycin+Mylotarg
NCT00085709 · Phase 3 · registry result, not featured evidence · combination
—Induction 7 + 3 + G.O.
NCT00085709 · Phase 3 · registry result, not featured evidence · combination
—Post-consolidation G.O.
NCT00085709 · Phase 3 · registry result, not featured evidence
23.1%
NCT00551460 · Phase 2 · registry result, not featured evidence · combination
—Cohort 1
NCT01698879 · Phase 2 · registry result, not featured evidence
0%Cohort 1 Version 2.0
NCT01698879 · Phase 2 · registry result, not featured evidence
0%Cohort 2
NCT01698879 · Phase 2 · registry result, not featured evidence
0%
NCT00882102 · Phase 2 · registry result, not featured evidence · combination
0%GO1 Dose Level Phase 1
NCT03531918 · Phase 1/2 · registry result, not featured evidence · combination
6.7%GO3 Dose Level Includes Phase 1 an
NCT03531918 · Phase 1/2 · registry result, not featured evidence · combination
Discontinued due to AEs
—a
NCT03727750 · Phase 4 · registry result, not featured evidence
show 10 more results
2.8%Ara-C+Daunomycin+Mylotarg
NCT00085709 · Phase 3 · registry result, not featured evidence · combination
—Induction 7 + 3 + G.O.
NCT00085709 · Phase 3 · registry result, not featured evidence · combination
—Post-consolidation G.O.
NCT00085709 · Phase 3 · registry result, not featured evidence
1.3%
NCT00551460 · Phase 2 · registry result, not featured evidence · combination
—Cohort 1
NCT01698879 · Phase 2 · registry result, not featured evidence
—Cohort 1 Version 2.0
NCT01698879 · Phase 2 · registry result, not featured evidence
—Cohort 2
NCT01698879 · Phase 2 · registry result, not featured evidence
—
NCT00882102 · Phase 2 · registry result, not featured evidence · combination
—GO1 Dose Level Phase 1
NCT03531918 · Phase 1/2 · registry result, not featured evidence · combination
—GO3 Dose Level Includes Phase 1 an
NCT03531918 · Phase 1/2 · registry result, not featured evidence · combination
Serious AEs
68%a
NCT03727750 · Phase 4 · registry result, not featured evidence
show 10 more results
—Ara-C+Daunomycin+Mylotarg
NCT00085709 · Phase 3 · registry result, not featured evidence · combination
16%Induction 7 + 3 + G.O.
NCT00085709 · Phase 3 · registry result, not featured evidence · combination
24.4%Post-consolidation G.O.
NCT00085709 · Phase 3 · registry result, not featured evidence
15.7%
NCT00551460 · Phase 2 · registry result, not featured evidence · combination
15%Cohort 1
NCT01698879 · Phase 2 · registry result, not featured evidence
—Cohort 1 Version 2.0
NCT01698879 · Phase 2 · registry result, not featured evidence
30%Cohort 2
NCT01698879 · Phase 2 · registry result, not featured evidence
2.5%
NCT00882102 · Phase 2 · registry result, not featured evidence · combination
16.7%GO1 Dose Level Phase 1
NCT03531918 · Phase 1/2 · registry result, not featured evidence · combination
16.7%GO3 Dose Level Includes Phase 1 an
NCT03531918 · Phase 1/2 · registry result, not featured evidence · combination
Most frequent reported AEs
a
febrile neutropenia 18%
hypokalaemia 18%
thrombocytopenia 18%
NCT03727750 · Phase 4 · registry result, not featured evidence
show 8 more results
febrile neutropenia 58.7%
nausea 56.3%
fatigue (asthenia, lethargy, malaise) 47.8%
NCT00085709 · Phase 3 · registry result, not featured evidence · combination
platelets 62.8%
fatigue (asthenia, lethargy, malaise) 52.6%
leukocytes (total wbc) 51.3%
NCT00085709 · Phase 3 · registry result, not featured evidence
ast, sgot 62.9%
pain - head/headache 62.9%
hemoglobin 57.1%
NCT00551460 · Phase 2 · registry result, not featured evidence · combination
grade 4 hematologic toxicity 100%
g1/2 hepatic toxicity 10%
grade i/ii infectous toxicity 10%
NCT01698879 · Phase 2 · registry result, not featured evidence
grade 4 hematologic toxicity 95%
grade 3 infectous toxicity 30%
grade i/ii infectous toxicity 25%
NCT01698879 · Phase 2 · registry result, not featured evidence
febrile neutropenia 50%
infection 10%
hemorhage 5%
NCT00882102 · Phase 2 · registry result, not featured evidence · combination
grade 3 enterocolitis 33.3%
grade 3 sepsis 33.3%
grade 3 bacteremia 16.7%
NCT03531918 · Phase 1/2 · registry result, not featured evidence · combination
grade 3 febrile neutropenia 93.3%
grade 3 hypertension 61.7%
grade 3 sepsis 46.7%
NCT03531918 · Phase 1/2 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Gemtuzumab Ozogamicin

CR + CRi 9.8% (n=51)
responder rate · % of participants
No placebo or comparator arm
NCT03727750 · Phase 4 · registry result, not featured evidence
Overall Survival 2.8 months
time to event · months
No placebo or comparator arm
NCT03727750 · Phase 4 · registry result, not featured evidence
show 1 more result
27.9 months
NCT00049517 · Phase 3 · registry result, not featured evidence
Disease-free Survival 13.6 months
time to event · months
No placebo or comparator arm
NCT00049517 · Phase 3 · registry result, not featured evidence
Disease-free Survival 39% (n=84) @ 104wk
absolute value · percentage points
No placebo or comparator arm
NCT00085709 · Phase 3 · registry result, not featured evidence
Complete Remission 69% (n=300) vs 68.6% (n=296) Ara-C+Daunomycin
responder rate · % of participants
NCT00085709 · Phase 3 · registry result, not featured evidence · combination · converted to % from 207 participants as posted
Event-free Survival 74% (n=70) @ 156wk
responder rate · % of participants
No placebo or comparator arm
NCT00551460 · Phase 2 · registry result, not featured evidence · combination
All-cause Mortality 11% (n=70) @ 6wk
responder rate · % of participants
No placebo or comparator arm
NCT00551460 · Phase 2 · registry result, not featured evidence · combination
Complete Remission NA @ 4wk
responder rate · count
No placebo or comparator arm
Complete Response
NCT01698879 · Phase 2 · registry result, not featured evidence
Complete Remission 90% (n=20) @ 4wk
responder rate · % of participants
No placebo or comparator arm
Complete Response
NCT01698879 · Phase 2 · registry result, not featured evidence · converted to % from 18 Participants as posted
show 1 more result
80% (n=20) @ 4wk*
Complete Response
NCT01698879 · Phase 2 · registry result, not featured evidence · converted to % from 16 Participants as posted
Relapse 30% (n=20) @ 26wk
responder rate · % of participants
No placebo or comparator arm
NCT01698879 · Phase 2 · registry result, not featured evidence
show 1 more result
59% (n=20) @ 26wk
NCT01698879 · Phase 2 · registry result, not featured evidence
Overall Survival 80% (n=20) @ 26wk
responder rate · % of participants
No placebo or comparator arm
NCT01698879 · Phase 2 · registry result, not featured evidence
show 2 more results
80% (n=20) @ 26wk
NCT01698879 · Phase 2 · registry result, not featured evidence
60% (n=60) @ 161wk
NCT03531918 · Phase 1/2 · registry result, not featured evidence · combination
Complete 25% (n=40) @ 2wk
responder rate · % of participants
No placebo or comparator arm
NCT00882102 · Phase 2 · registry result, not featured evidence · combination · converted to % from 10 Participants as posted

+ 7 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Anti-CD33 CAR T-cells's landscape · Gemtuzumab Ozogamicin's landscape